Notwithstanding numerous setbacks, several MDM2 inhibitors have now progressed into late-phase clinical development. New tactics have also been made to reinforce the efficacy of MDM2 inhibitors and also to mitigate their on-concentrate on toxicity. In this review, we summarize the development and problems in the development of the MDM2 targeted https://felixsxcim.mdkblog.com/37457411/the-smart-trick-of-dorsomorphin-that-no-one-is-discussing